Invention Grant
- Patent Title: Heterocyclic degronimers for target protein degradation
-
Application No.: US17164446Application Date: 2021-02-01
-
Publication No.: US12076405B2Publication Date: 2024-09-03
- Inventor: Andrew J. Phillips , Christopher G. Nasveschuk , James A. Henderson , Yanke Liang , Mark E. Fitzgerald , Minsheng He , Ryan E. Michael
- Applicant: C4 Therapeutics, Inc.
- Applicant Address: US MA Watertown
- Assignee: C4 Therapeutics, Inc.
- Current Assignee: C4 Therapeutics, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Knowles Intellectual Property Strategies, LLC
- The original application number of the division: US16186339 2018.11.09
- Main IPC: A61K47/54
- IPC: A61K47/54 ; A61K31/4035 ; A61K31/438 ; A61K31/439 ; A61K31/454 ; A61K31/547 ; A61K31/55 ; C07D401/04 ; C07D403/04
Abstract:
This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
Public/Granted literature
- US20230014124A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION Public/Granted day:2023-01-19
Information query
